Hematopoietic Cell Transplantation PDQ®

In brief

Evidence-based clinical reference from the National Cancer Institute for healthcare professionals managing pediatric hematopoietic cell transplantation. Covers indications, protocols, and outcomes for stem cell and bone marrow transplantation in children with hematologic malignancies and other conditions requiring cellular therapy.

• Hematopoietic cell transplantation (HCT) is a curative treatment option for various pediatric malignancies and non-malignant hematologic disorders.
• Transplant types include autologous (patient's own cells) and allogeneic (donor cells), each with distinct indications and risk profiles.
• Graft-versus-host disease (GVHD) remains a major complication of allogeneic HCT, requiring careful immunosuppression management.
• Conditioning regimens (chemotherapy ± radiation) prepare the patient for transplant but carry significant toxicity risks in children.
• Long-term survivorship care is essential post-HCT due to risks of secondary malignancies, organ dysfunction, and growth/developmental issues.

Written by the GCMD Library team from the guideline.